标题
Immunotherapy of multiple myeloma
作者
关键词
-
出版物
JOURNAL OF CLINICAL INVESTIGATION
Volume 130, Issue 4, Pages 1565-1575
出版商
American Society for Clinical Investigation
发表日期
2020-03-09
DOI
10.1172/jci129205
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
- (2020) Shih-Feng Cho et al. BLOOD
- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- (2019) Chuang Sun et al. Oncotarget
- Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
- (2019) Roberta Demichelis-Gómez et al. Current Oncology Reports
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
- (2019) Christina L. Zuch de Zafra et al. CLINICAL CANCER RESEARCH
- A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- (2019) Anita D'Souza et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Chimeric antigen receptor T cell persistence and memory cell formation
- (2019) Alexander D McLellan et al. IMMUNOLOGY AND CELL BIOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
- (2019) Shiping Jiao et al. CELL
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
- (2019) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- c-Jun overexpression in CAR T cells induces exhaustion resistance
- (2019) Rachel C. Lynn et al. NATURE
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- Vaccine therapy in hematologic malignancies
- (2018) David Avigan et al. BLOOD
- Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
- (2018) Myrna R. Nahas et al. BLOOD REVIEWS
- Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
- (2018) Kyohei Nakamura et al. CANCER CELL
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017
- (2018) Xuejiao Yin et al. Cancer Cell International
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Global Burden of Multiple Myeloma
- (2018) Andrew J. Cowan et al. JAMA Oncology
- CrbnI391Vis sufficient to conferin vivosensitivity to thalidomide and its derivatives in mice
- (2018) Emma C. Fink et al. BLOOD
- Myeloma-escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade
- (2018) Simone A. Minnie et al. BLOOD
- IMiDs through loss of Ikaros and Aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38
- (2018) Pasquale L. Fedele et al. BLOOD
- Abstract LB-114: a-TIGIT antagonist antibody EOS884448 shows dual mechanism of action by restoration of T cell effector functions and preferential depletion of Treg
- (2018) XAVIER LEROY et al. CANCER RESEARCH
- Abstract 1727: Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models
- (2018) Natalie A. Bezman et al. CANCER RESEARCH
- Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
- (2018) Ankit K. Dutta et al. LEUKEMIA
- Bone marrow transplantation generates T cell–dependent control of myeloma in mice
- (2018) Slavica Vuckovic et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunotherapy Combinations in Multiple Myeloma — Known Unknowns
- (2018) Nicole J. Gormley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression
- (2018) Arianna Calcinotto et al. Nature Communications
- Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
- (2018) Kerry S. Campbell et al. Frontiers in Immunology
- Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma
- (2017) Q Wang et al. LEUKEMIA
- Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma
- (2017) Jian-Yang Ao et al. MOLECULAR CANCER THERAPEUTICS
- High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
- (2017) A Miller et al. Blood Cancer Journal
- Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma
- (2017) Sara J. McKee et al. Cancer Immunology Research
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
- (2016) V. Hoyos et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
- (2016) Camille Guillerey et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
- (2016) Claudia Zelle-Rieser et al. Journal of Hematology & Oncology
- Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
- (2016) H Suen et al. LEUKEMIA
- Genomic complexity of multiple myeloma and its clinical implications
- (2016) Salomon Manier et al. Nature Reviews Clinical Oncology
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
- (2016) M. Ishibashi et al. Cancer Immunology Research
- Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
- (2015) Bruno Paiva et al. BLOOD
- Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing
- (2015) P. Leone et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Marrow Infiltrating Lymphocytes
- (2015) Kimberly A. Noonan et al. CANCER JOURNAL
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent
- (2015) Camille Guillerey et al. JOURNAL OF CLINICAL INVESTIGATION
- Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+T Cells
- (2015) Xiaoyun Lu et al. JOURNAL OF IMMUNOLOGY
- Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
- (2015) R H Prabhala et al. LEUKEMIA
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma
- (2015) Kimberly A. Noonan et al. Science Translational Medicine
- Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
- (2015) S Yousef et al. Blood Cancer Journal
- Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
- (2015) Liang Wang et al. Oncotarget
- T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
- (2015) D. J. Chung et al. Cancer Immunology Research
- Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
- (2015) Weiqing Jing et al. Journal for ImmunoTherapy of Cancer
- Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
- (2014) Erin Gatza et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma
- (2014) M. E. Murray et al. BLOOD
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
- (2014) Aaron P. Rapoport et al. CLINICAL CANCER RESEARCH
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Serial exome analysis of disease progression in premalignant gammopathies
- (2014) S Zhao et al. LEUKEMIA
- Potential relationship and clinical significance of miRNAs and Th17 cytokines in patients with multiple myeloma
- (2014) Yanjie Li et al. LEUKEMIA RESEARCH
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma
- (2013) T. J. Kearl et al. JOURNAL OF IMMUNOLOGY
- Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
- (2013) B A Walker et al. LEUKEMIA
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- The IL-17 Differentiation Pathway and Its Role in Transplant Outcome
- (2012) Jonathan S. Serody et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Lenalidomide enhances anti-myeloma cellular immunity
- (2012) Katarina Luptakova et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
- (2012) Jean-Jacques Fournié et al. Cellular & Molecular Immunology
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
- (2011) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
- (2011) J. Martinez-Lopez et al. BLOOD
- Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges
- (2011) Madhav V. Dhodapkar et al. CLINICAL IMMUNOLOGY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
- (2010) R. H. Prabhala et al. BLOOD
- Natural killer cell activity in monoclonal gammopathies: Relation to disease activity
- (2010) A. Österborg et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
- (2010) M. K. Brimnes et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
- (2009) Martha Q. Lacy et al. AMERICAN JOURNAL OF HEMATOLOGY
- Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma
- (2009) V. Racanelli et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
- (2009) Y. Zheng et al. BLOOD
- Role of autologous and allogeneic stem cell transplantation in myeloma
- (2009) W I Bensinger LEUKEMIA
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies
- (2008) Marta Chesi et al. CANCER CELL
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
- (2008) O. Murillo et al. CLINICAL CANCER RESEARCH
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started